OR8I2

Across TCGA pan-cancer cohorts, OR8I2 RNA is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR8I2 data layer compared with 7 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OR8I2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR8I2 expression acts as an unfavorable survival marker.

STAD, KIRC, and TGCT are the cancer types where OR8I2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	II,III,IV	0.246	0.539	.001	90	view →
KIRC	DFS	Tertile	IV	0.109	0.640	<.001	36	view →
TGCT	DFS	Tertile	II,III,IV	0.015	0.919	<.001	36	view →
HNSC	DFS	Tertile	III,IV	0.152	0.596	.013	27	view →
BRCA	DFS	Tertile	All	0.661	0.903	.002	24	view →
SKCM	DFS	Tertile	II,III,IV	0.224	0.712	.005	24	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR8I2–STAD (DFS)

Open the STAD breakdown →